Clinical trial
A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia
NCT02690714 · Prometic Biotherapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02690714 |
|---|---|
| Title | A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia |
| Official title | A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia |
| Lead sponsor | Prometic Biotherapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Hypoplasminogenemia, Congenital Plasminogen Deficiency |
| Intervention type | Biological |
| Interventions | Plasminogen (Human) intravenous |
| Enrollment | 15 |
| Start date | May 4, 2016 |
| Primary completion | Dec 17, 2017 |
| Completion | Oct 8, 2018 |
| First posted | Feb 24, 2016 |
| Last update posted | Aug 2, 2021 |
| Countries | Norway, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: